UTRN

Utrophin (UTRN) is an autosomal dystrophin-related protein concentrated near acetylcholine receptors at the neuromuscular junction in normal muscle and present in vascular smooth muscle and proliferating cell lines, that redistributes to the non-junctional sarcolemma in Duchenne muscular dystrophy muscle where dystrophin is absent (PMID:1757469). Its expression is post-transcriptionally restrained during skeletal muscle differentiation through a MyoD-driven program in which MyoD directly transactivates miR-206, and miR-206 targets the UTRN 3' UTR to suppress utrophin levels (PMID:17030984); utrophin transcription is positively controlled by CCN5, which acts on the utrophin promoter and can upregulate its expression in mdx/utrn(±) muscle (PMID:35557546). Beyond muscle, UTRN behaves as a tumor suppressor: its loss promotes cellular transformation while restoring wild-type UTRN inhibits cancer cell growth and tumor formation, and inactivating mutations occur in breast cancer, neuroblastoma, and melanoma (PMID:17384672), with growth suppression mediated in part by dampening p38 and JNK1/c-Jun MAPK signaling (PMID:33632212). Biallelic loss-of-function variants in UTRN cause an autosomal recessive multiple congenital arthrogryposis syndrome, establishing a requirement for utrophin in normal musculoskeletal and multi-organ development (PMID:41244983).

1. 1991 High

   Established where the dystrophin homologue utrophin resides in tissue, defining its normal junctional localization and its capacity to occupy the sarcolemma when dystrophin is missing.

   Evidence Immunolocalization with a panel of 19 epitope-specific monoclonal antibodies plus Western blotting across normal, mdx, and Duchenne muscular dystrophy muscle and other tissues

   PMID:1757469

   Open questions at the time

   • Did not define the molecular basis of redistribution to non-junctional sarcolemma
   • No binding partners or membrane-anchoring complex identified
   • Functional consequence of the localization not tested
2. 2006 High

   Resolved how utrophin is downregulated during myogenesis, identifying a MyoD→miR-206→UTRN 3' UTR axis as the post-transcriptional brake on its expression.

   Evidence Reporter assays of the Utrn 3' UTR, miR-206 gain-of-function in MyoD-converted fibroblasts, and promoter/ChIP analysis of MyoD activation of miR-206

   PMID:17030984

   Open questions at the time

   • Did not address whether this axis can be exploited to elevate utrophin therapeutically
   • Other regulators of UTRN expression not surveyed
3. 2007 Medium

   Recast utrophin as a tumor suppressor, showing its loss drives transformation and its restoration inhibits tumor growth, with recurrent inactivating mutations in multiple cancers.

   Evidence Antisense-induced transformation screen, wild-type UTRN overexpression in breast cancer cells with in vitro growth assay and nude mouse xenograft, and RT-PCR/in vitro transcription-translation mutation analysis

   PMID:17384672

   Open questions at the time

   • Single lab; tumor-suppressor mechanism not defined in this study
   • Mutation frequencies across tumor cohorts not quantified
   • Domain(s) required for growth suppression unmapped
4. 2021 Medium

   Provided a signaling mechanism for utrophin's growth suppression, placing it upstream of p38 and JNK1/c-Jun MAPK activity in melanoma.

   Evidence Stable UTRN overexpression in A375 melanoma cells with CCK-8/EdU proliferation assays, Western blot for p38/JNK1/c-Jun, and pharmacological rescue using an Epac activator

   PMID:33632212

   Open questions at the time

   • Single cell line and single lab
   • Direct molecular link between utrophin and MAPK components not established
   • Whether the same pathway operates in other tumor types untested
5. 2022 Medium

   Identified a positive transcriptional regulator of utrophin, showing CCN5 acts on the utrophin promoter to upregulate its expression in a dystrophic muscle context.

   Evidence AAV9-mediated CCN5 gene transfer in mdx/utrn(±) mice, utrophin promoter assay, and RNA-seq

   PMID:35557546

   Open questions at the time

   • Direct CCN5 occupancy of the utrophin promoter not shown
   • Mechanism linking secreted CCN5 to utrophin transcription unresolved
   • Single lab
6. 2025 Medium

   Connected UTRN loss to a human Mendelian phenotype, showing biallelic loss-of-function causes a recessive multiple congenital arthrogryposis syndrome.

   Evidence Trio whole-genome sequencing with RNA-seq confirmation of aberrant splicing and a truncated protein isoform

   PMID:41244983

   Open questions at the time

   • Single case; genotype-phenotype spectrum unknown
   • Developmental mechanism linking utrophin loss to arthrogryposis not defined
   • No functional rescue demonstrated

• How utrophin's membrane-anchoring/cytoskeletal role mechanistically intersects with its tumor-suppressive and developmental functions remains unresolved.
• No direct binding partners or complex composition characterized in the corpus
• No structural model linking domains to its distinct functions
• Mechanism by which utrophin restrains MAPK signaling not molecularly defined